microLIQUID is now a TE Connectivity Company. Read More
Molecular diagnostics have improved the diagnosis and treatment of millions of patients worldwide allowing clinicians to diagnose patients earlier as well as providing better ongoing therapies.
At microLIQUID we develop fully automated sample preparation and molecular diagnostic systems based on microfluidics.
Non-microfluidic diagnostic instruments usually require an important quantity of costly reagents, long analysis time, established lab infrastructure and trained professionals to operate, which limits their availability for large-scale screening applications in developed countries and primary care in developing countries. There is a strong demand for robust, cost-effective, and simple-to-operate instruments for molecular diagnostics.
Microfluidics systems have many advantages, such as short analysis time, reduction in fabrication costs, and low sample/reagent consumption.
Besides, most current microfluidic diagnostic devices are designed to target a single disease, such as a given cancer or a variety of pathogens. The future of molecular diagnostics lies in highly multiplexed microfluidic devices that can screen for potentially hundreds of diseases simultaneously.
microLIQUID is committed with the development of diagnostic systems, having the experience and expertise to develop and manufacture fully automated sample preparation and molecular diagnostics systems.
microLIQUID – MICROFLUIDIC IMMUNOASSAY
The high sensitivity and specificity of immunoassays make them a powerful tool in molecular diagnostics. microLIQUID, has proven that microfluidics is making a change in the field of diagnostics.
The current immunoassay ‘gold standard’ ELISA, while proven to be highly robust and reliable, suffers from large sample requirements, long diffusion times, and hence, long incubation times moreover, it requires a specific enzyme-fluorophore complex that does not interfere with the reaction.
In recent years, microLIQUID has focused on combining the classic ELISA approach with microfluidic technologies. Such devices enable quantitative immunoassay results by integrating sensitive optical or electrochemical detection methods. The main advantages of a microfluidic immunoassay compared to conventional approaches are:
1. Increase throughout and reproducibility, with automatic microfluidic immunoassay system.
2. Lower consumption of samples and reagents.
3. Speed up the antibody-antigen binding reactions.
Summarizing, the combination of microfluidics and immunoassay technologies can detect biomarkers with faster assay time, reduced volumes of reagents, lower power requirements, and higher levels of integration and automation compared to traditional approaches.